The facility is 75 per cent automated, boosting annual capacity to over a million units
Axio Biosolutions, recently expanded its manufacturing facility at Gujarat Pharma Techno Park in Ahmedabad to over a million units annually. Its manufacturing facility is ISO 13485 certified and GMP approved, with an ISO 7, Class 10000 cleanroom. Now, the factory is 75 per cent automated, boosting the annual capacity to over a million units.
Commenting on the latest development, Gourav Maheshwari, Director, Finance and Operations, said, “Our products are proudly made in India for the global market. With this expansion along with US FDA clearance for our products we are closer to realising our aspirations to become a global medtech company from India. We have created more than 100 jobs for local community with a significant contribution of women staff, we believe this facility will set a benchmark for medtech manufacturing in India.“
Axio Biosolutions recently announced its Scientific Advisory Board, comprising Dr Shiladitya Sengupta, Assistant Professor of Medicine, Harvard Medical School, as Chairman and Dr S V Mahadevan, Professor of Emergency Medicine, Stanford University, as member.
Last year, the company raised $7.4mn in a Series B funding round led by Ratan Tata’s UC- RNT, along with existing investors Accel Partners and IDG Ventures India.